In addition, PPARγ agonists, prostaglandin J2 (PGJ2), ciglitazone, troglitazone, and GW1929 have been shown to inhibit the growth of lung carcinoma cells by upregulating p21 levels and reducing cyclin D1 expression [47]. Here, PPARG is linked to lung carcinoma.